BVNRYライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (27 4月 2024 @ 00:20):

Stats
本日の出来高	892.00
平均出来高	5 243.00
時価総額	1.65B
EPS	$0 ( 2024-03-07 )
次の収益日	( $0 ) 2024-05-14
Last Dividend	$0.593 ( 2020-03-27 )
Next Dividend	$0 ( N/A )
P/E	7.66
ATR14	$0 (0.00%)

Bavarian Nordic A/S 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Bavarian Nordic A/S 財務諸表

Annual	2023
収益:	$7.06B
総利益:	$4.52B (64.07 %)
EPS:	$19.23

FY	2023
収益:	$7.06B
総利益:	$4.52B (64.07 %)
EPS:	$19.23

FY	2023
収益:	$0
総利益:	$0 (0.00 %)
EPS:	$0

FY	2022
収益:	$3.15B
総利益:	$1.70B (53.99 %)
EPS:	$-4.93

Financial Reports:

No articles found.

Bavarian Nordic A/S Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Bavarian Nordic A/S Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.34 - Potential for dividend initiation, but uncertain (13.19%)

Information

First Dividend	$0.593	2020-03-27
Last Dividend	$0.593	2020-03-27
Next Dividend	$0	N/A
Payout Date	2020-04-06
Next Payout Date	N/A
# dividends	1	--
Total Paid Out	$0.593	--
Avg. Dividend % Per Year	0.00%	--
Score	2.27	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	4.34
Div. Directional Score	7.53	--

Next Divdend (Est)
(2024-04-28)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

2.27

Pay Frequency

Insufficient data to determine frequency

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
RSTRF	Ex Dividend Knight	2023-09-19	Semi-Annually	0.00%
FFWC	Ex Dividend Knight	2023-09-14	Quarterly	0.00%
WDFN	Ex Dividend Junior	2023-08-10	Quarterly	0.00%
MAAL	Ex Dividend Knight	2023-09-22	Quarterly	0.00%
CLPHY	Ex Dividend Knight	2023-09-01	Quarterly	0.00%
SMFKY	Ex Dividend Knight	2023-09-28	Semi-Annually	0.00%
HAWPY	Ex Dividend Knight	2023-08-22	Semi-Annually	0.00%
AMCCF	Ex Dividend Knight	2023-09-06	Quarterly	0.00%
NGLOY	Ex Dividend Knight	2023-08-17	Semi-Annually	0.00%
CSLLY	Ex Dividend Knight	2023-09-08	Semi-Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.209	1.500	5.82	8.74	[0 - 0.5]
returnOnAssetsTTM	0.103	1.200	6.57	7.89	[0 - 0.3]
returnOnEquityTTM	0.153	1.500	9.41	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	1.938	0.800	5.31	4.25	[1 - 3]
quickRatioTTM	1.342	0.800	6.81	5.45	[0.8 - 2.5]
cashRatioTTM	0.530	1.500	8.17	10.00	[0.2 - 2]
debtRatioTTM	0.00430	-1.500	9.93	-10.00	[0 - 0.6]
interestCoverageTTM	25.16	1.000	1.793	1.793	[3 - 30]
operatingCashFlowPerShareTTM	14.59	2.00	5.14	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.849	2.00	9.08	10.00	[0 - 20]
debtEquityRatioTTM	0.00597	-1.500	9.98	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.652	1.000	2.47	2.47	[0.2 - 0.8]
operatingProfitMarginTTM	0.215	1.000	7.70	7.70	[0.1 - 0.6]
cashFlowToDebtRatioTTM	18.15	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.492	0.800	-0.0521	-0.0416	[0.5 - 2]
Total Score				10.72

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	2.55	1.000	9.84	0	[1 - 100]
returnOnEquityTTM	0.153	2.50	9.62	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.849	2.00	9.38	10.00	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	14.59	2.00	5.14	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.00228	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.158	1.000	8.54	0	[0.1 - 0.5]
Total Score				4.34

Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.